

References

S-5044

1. Rome BN, Kramer DB, Kesselheim AS. FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012. *JAMA*. Jan 2014; 311(4): 385-91. PMID 24449317
2. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in individuals with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. *N Engl J Med*. Dec 26 1996; 335(26): 1933-40. PMID 8960472
3. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in individuals with myocardial infarction and reduced ejection fraction. *N Engl J Med*. Mar 21 2002; 346(12): 877-83. PMID 11907286
4. Bigger JT. Prophylactic use of implanted cardiac defibrillators in individuals at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. *N Engl J Med*. Nov 27 1997; 337(22): 1569-75. PMID 9371853
5. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in individuals with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. *N Engl J Med*. Dec 16 1999; 341(25): 1882-90. PMID 10601507
6. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med*. Jan 20 2005; 352(3): 225-37. PMID 15659722
7. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. *N Engl J Med*. Dec 09 2004; 351(24): 2481-8. PMID 15590950
8. Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. *N Engl J Med*. Oct 08 2009; 361(15): 1427-36. PMID 19812399
9. Raviele A, Bongiorno MG, Brignole M, et al. Early EPS/ICD strategy in survivors of acute myocardial infarction with severe left ventricular dysfunction on optimal beta-blocker treatment. The BETA-blocker STRategy plus ICD trial. *Europace*. Jul 2005; 7(4): 327-37. PMID 16028343
10. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in individuals with nonischemic dilated cardiomyopathy. *N Engl J Med*. May 20 2004; 350(21): 2151-8. PMID 15152060
11. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med*. May 20 2004; 350(21): 2140-50. PMID 15152059

12. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in individuals with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. *J Am Coll Cardiol*. May 21 2003; 41(10): 1707-12. PMID 12767651
13. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). *Circulation*. Mar 26 2002; 105(12): 1453-8. PMID 11914254
14. Kober L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Individuals with Nonischemic Systolic Heart Failure. *N Engl J Med*. Sep 29 2016; 375(13): 1221-30. PMID 27571011
15. Woods B, Hawkins N, Mealing S, et al. Individual individual data network meta-analysis of mortality effects of implantable cardiac devices. *Heart*. Nov 2015; 101(22): 1800-6. PMID 26269413
16. Wolff G, Lin Y, Karathanos A, et al. Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials. *Clin Res Cardiol*. Jul 2017; 106(7): 501-513. PMID 28213711
17. Stavrakis S, Asad Z, Reynolds D. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Individuals With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. *J Cardiovasc Electrophysiol*. Jun 2017; 28(6): 659-665. PMID 28316104
18. Akel T, Lafferty J. Implantable cardioverter defibrillators for primary prevention in individuals with nonischemic cardiomyopathy: A systematic review and meta-analysis. *Cardiovasc Ther*. Jun 2017; 35(3). PMID 28129469
19. Golwala H, Bajaj NS, Arora G, et al. Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis. *Circulation*. Jan 10 2017; 135(2): 201-203. PMID 27993908
20. Earley A, Persson R, Garlitski AC, et al. Effectiveness of implantable cardioverter defibrillators for primary prevention of sudden cardiac death in subgroups a systematic review. *Ann Intern Med*. Jan 21 2014; 160(2): 111-21. PMID 24592496
21. Fontenla A, Martinez-Ferrer JB, Alzueta J, et al. Incidence of arrhythmias in a large cohort of individuals with current implantable cardioverter-defibrillators in Spain: results from the UMBRELLA Registry. *Europace*. Nov 2016; 18(11): 1726-1734. PMID 26705555
22. Schinkel AF, Vriesendorp PA, Sijbrands EJ, et al. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. *Circ Heart Fail*. Sep 01 2012; 5(5): 552-9. PMID 22821634

23. Magnusson P, Gadler F, Liv P, et al. Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery. *J Cardiovasc Electrophysiol*. Oct 2015; 26(10): 1088-94. PMID 26178879
24. Horner JM, Kinoshita M, Webster TL, et al. Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a single-center experience. *Heart Rhythm*. Nov 2010; 7(11): 1616-22. PMID 20816872
25. Hernandez-Ojeda J, Arbelo E, Borrás R, et al. Individuals With Brugada Syndrome and Implanted Cardioverter-Defibrillators: Long-Term Follow-Up. *J Am Coll Cardiol*. Oct 17 2017; 70(16): 1991-2002. PMID 29025556
26. Conte G, Sieira J, Ciconte G, et al. Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience. *J Am Coll Cardiol*. Mar 10 2015; 65(9): 879-88. PMID 25744005
27. Dores H, Reis Santos K, Adragao P, et al. Long-term prognosis of individuals with Brugada syndrome and an implanted cardioverter-defibrillator. *Rev Port Cardiol*. Jun 2015; 34(6): 395-402. PMID 26028488
28. Roses-Noguer F, Jarman JW, Clague JR, et al. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm*. Jan 2014; 11(1): 58-66. PMID 24120999
29. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. *Heart Rhythm*. Jul 2014; 11(7): 1305-23. PMID 24819193
30. Plitt A, Dorbala S, Albert MA, et al. Cardiac sarcoidosis: case report, workup, and review of the literature. *Cardiol Ther*. Dec 2013; 2(2): 181-97. PMID 25135396
31. Mantini N, Williams B, Stewart J, et al. Cardiac sarcoid: a clinician's review on how to approach the individual with cardiac sarcoid. *Clin Cardiol*. 2012; 35(7): 410-5. PMID 22499155
32. Berul CI, Van Hare GF, Kertesz NJ, et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease individuals. *J Am Coll Cardiol*. Apr 29 2008; 51(17): 1685-91. PMID 18436121
33. Silka MJ, Kron J, Dunnigan A, et al. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric individuals. The Pediatric Electrophysiology Society. *Circulation*. Mar 1993; 87(3): 800-7. PMID 8443901
34. Alexander ME, Cecchin F, Walsh EP, et al. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. *J Cardiovasc Electrophysiol*. Jan 2004; 15(1): 72-6. PMID 15028076
35. Lewandowski M, Sterlinski M, Maciag A, et al. Long-term follow-up of children and young adults treated with implantable cardioverter-defibrillator:

- the authors' own experience with optimal implantable cardioverter-defibrillator programming. *Europace*. Sep 2010; 12(9): 1245-50. PMID 20650939
- 36.. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in individuals resuscitated from near-fatal ventricular arrhythmias. *N Engl J Med*. Nov 27 1997; 337(22): 1576-83. PMID 9411221
 37. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in individuals resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). *Circulation*. Aug 15 2000; 102(7): 748-54. PMID 10942742
 38. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. *Circulation*. Mar 21 2000; 101(11): 1297-302. PMID 10725290
 39. Nademanee K, Veerakul G, Mower M, et al. Defibrillator Versus beta-Blockers for Unexplained Death in Thailand (DEBUT): a randomized clinical trial. *Circulation*. May 06 2003; 107(17): 2221-6. PMID 12695290
 40. Wever EF, Hauer RN, van Capelle FL, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. *Circulation*. Apr 15 1995; 91(8): 2195-203. PMID 7697849
 41. Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. *J Am Coll Cardiol*. May 07 2003; 41(9): 1573-82. PMID 12742300
 42. National Institute for Health and Care Excellence (NICE). Overview: Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (Review of TA95 and TA120). 2013; <https://www.guidelinecentral.com/summaries/implantable-cardioverter-defibrillators-and-cardiac-resynchronisation-therapy-for-arrhythmias-and-heart-failure-review-of-ta95-and-ta120/>. Accessed April 20, 2020.
 43. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. *Eur Heart J*. Dec 2000; 21(24): 2071-8. PMID 11102258
 44. Betts TR, Sadarmin PP, Tomlinson DR, et al. Absolute risk reduction in total mortality with implantable cardioverter defibrillators: analysis of primary and secondary prevention trial data to aid risk/benefit analysis. *Europace*. Jun 2013; 15(6): 813-9. PMID 23365069
 45. Chan PS, Hayward RA. Mortality reduction by implantable cardioverter-defibrillators in high-risk individuals with heart failure, ischemic heart disease,

- and new-onset ventricular arrhythmia: an effectiveness study. *J Am Coll Cardiol*. May 03 2005; 45(9): 1474-81. PMID 15862422
46. Persson R, Earley A, Garlitski AC, et al. Adverse events following implantable cardioverter defibrillator implantation: a systematic review. *J Interv Card Electrophysiol*. Aug 2014; 40(2): 191-205. PMID 24948126
 47. Ezzat VA, Lee V, Ahsan S, et al. A systematic review of ICD complications in randomised controlled trials versus registries: is our 'real-world' data an underestimation?. *Open Heart*. 2015; 2(1): e000198. PMID 25745566
 48. Kirkfeldt RE, Johansen JB, Nohr EA, et al. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. *Eur Heart J*. May 2014; 35(18): 1186-94. PMID 24347317
 49. van Rees JB, de Bie MK, Thijssen J, et al. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. *J Am Coll Cardiol*. Aug 30 2011; 58(10): 995-1000. PMID 21867832
 50. Olde Nordkamp LR, Postema PG, Knops RE, et al. Implantable cardioverter-defibrillator harm in young individuals with inherited arrhythmia syndromes: A systematic review and meta-analysis of inappropriate shocks and complications. *Heart Rhythm*. Feb 2016; 13(2): 443-54. PMID 26385533
 51. Food and Drug Administration. Premature Insulation Failure in Recalled Riata Implantable Cardioverter Defibrillator (ICD) Leads Manufactured by St. Jude Medical, Inc.: FDA Safety Communication. 2014; <https://wayback.archive-it.org/7993/20170722215745/https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm314930.htm>. Accessed April 20, 2020.
 52. Hauser RG, Katsiyannis WT, Gornick CC, et al. Deaths and cardiovascular injuries due to device-assisted implantable cardioverter-defibrillator and pacemaker lead extraction. *Europace*. Mar 2010; 12(3): 395-401. PMID 19946113
 53. Providencia R, Kramer DB, Pimenta D, et al. Transvenous Implantable Cardioverter-Defibrillator (ICD) Lead Performance: A Meta-Analysis of Observational Studies. *J Am Heart Assoc*. Oct 30 2015; 4(11). PMID 26518666
 54. Birnie DH, Parkash R, Exner DV, et al. Clinical predictors of Fidelis lead failure: report from the Canadian Heart Rhythm Society Device Committee. *Circulation*. Mar 13 2012; 125(10): 1217-25. PMID 22311781
 55. Hauser RG, Maisel WH, Friedman PA, et al. Longevity of Sprint Fidelis implantable cardioverter-defibrillator leads and risk factors for failure: implications for individual management. *Circulation*. Feb 01 2011; 123(4): 358-63. PMID 21242478

56. Gould PA, Gula LJ, Champagne J, et al. Outcome of advisory implantable cardioverter-defibrillator replacement: one-year follow-up. *Heart Rhythm*. Dec 2008; 5(12): 1675-81. PMID 19084804
57. Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. *Circulation*. Oct 19 2010; 122(16): 1553-61. PMID 20921437
58. Ricci RP, Pignalberi C, Magris B, et al. Can we predict and prevent adverse events related to high-voltage implantable cardioverter defibrillator lead failure?. *J Interv Card Electrophysiol*. Jan 2012; 33(1): 113-21. PMID 21882010
59. Cheng A, Wang Y, Curtis JP, et al. Acute lead dislodgements and in-hospital mortality in individuals enrolled in the national cardiovascular data registry implantable cardioverter defibrillator registry. *J Am Coll Cardiol*. Nov 09 2010; 56(20): 1651-6. PMID 21050975
60. Faulknier BA, Traub DM, Aktas MK, et al. Time-dependent risk of Fidelis lead failure. *Am J Cardiol*. Jan 01 2010; 105(1): 95-9. PMID 20102898
61. Smit J, Korup E, Schonheyder HC. Infections associated with permanent pacemakers and implanted cardioverter-defibrillator devices. A 10-year regional study in Denmark. *Scand J Infect Dis*. Sep 2010; 42(9): 658-64. PMID 20465488
62. Nery PB, Fernandes R, Nair GM, et al. Device-related infection among individuals with pacemakers and implantable defibrillators: incidence, risk factors, and consequences. *J Cardiovasc Electrophysiol*. Jul 2010; 21(7): 786-90. PMID 20102431
63. Sohail MR, Hussain S, Le KY, et al. Risk factors associated with early- versus late-onset implantable cardioverter-defibrillator infections. *J Interv Card Electrophysiol*. Aug 2011; 31(2): 171-83. PMID 21365264
64. Chua JD, Wilkoff BL, Lee I, et al. Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. *Ann Intern Med*. Oct 17 2000; 133(8): 604-8. PMID 11033588
65. Borleffs CJ, Thijssen J, de Bie MK, et al. Recurrent implantable cardioverter-defibrillator replacement is associated with an increasing risk of pocket-related complications. *Pacing Clin Electrophysiol*. Aug 2010; 33(8): 1013-9. PMID 20456647
66. Daubert JP, Zareba W, Cannom DS, et al. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. *J Am Coll Cardiol*. Apr 08 2008; 51(14): 1357-65. PMID 18387436
67. Tan VH, Wilton SB, Kuriachan V, et al. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies

- on mortality: a systematic review and meta-analysis. *Circ Arrhythm Electrophysiol.* Feb 2014; 7(1): 164-70. PMID 24446023
68. Sterns LD, Meine M, Kurita T, et al. Extended detection time to reduce shocks is safe in secondary prevention individuals: The secondary prevention substudy of PainFree SST. *Heart Rhythm.* Jul 2016; 13(7): 1489-96. PMID 26988379
69. Auricchio A, Schloss EJ, Kurita T, et al. Low inappropriate shock rates in individuals with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. *Heart Rhythm.* May 2015; 12(5): 926-36. PMID 25637563
70. Lee DS, Krahn AD, Healey JS, et al. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. *J Am Coll Cardiol.* Feb 23 2010; 55(8): 774-82. PMID 20170816
71. Furniss G, Shi B, Jimenez A, et al. Cardiac troponin levels following implantable cardioverter defibrillation implantation and testing. *Europace.* Feb 2015; 17(2): 262-6. PMID 25414480
72. Mithani AA, Kath H, Hunter K, et al. Characteristics and early clinical outcomes of individuals undergoing totally subcutaneous vs. transvenous single chamber implantable cardioverter defibrillator placement. *Europace.* Feb 01 2018; 20(2): 308-314. PMID 28383717
73. Honarbakhsh S, Providencia R, Srinivasan N, et al. A propensity matched case-control study comparing efficacy, safety and costs of the subcutaneous vs. transvenous implantable cardioverter defibrillator. *Int J Cardiol.* Feb 01 2017; 228: 280-285. PMID 27865198
74. Kobe J, Hucklenbroich K, Geisendorfer N, et al. Posttraumatic stress and quality of life with the totally subcutaneous compared to conventional cardioverter-defibrillator systems. *Clin Res Cardiol.* May 2017; 106(5): 317-321. PMID 27878381
75. Pedersen SS, Mastenbroek MH, Carter N, et al. A Comparison of the Quality of Life of Patients With an Entirely Subcutaneous Implantable Defibrillator System Versus a Transvenous System (from the EFFORTLESS S-ICD Quality of Life Substudy). *Am J Cardiol.* Aug 15 2016; 118(4): 520-6. PMID 27353211
76. Brouwer TF, Yilmaz D, Lindeboom R, et al. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. *J Am Coll Cardiol.* Nov 08 2016; 68(19): 2047-2055. PMID 27810043
77. Friedman DJ, Parzynski CS, Varosy PD, et al. Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States. *JAMA Cardiol.* Nov 01 2016; 1(8): 900-911. PMID 27603935
78. Kobe J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a

- multicenter case-control study. *Heart Rhythm*. Jan 2013; 10(1): 29-36. PMID 23032867
79. Lambiase PD, Barr C, Theuns DA, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. *Eur Heart J*. Jul 01 2014; 35(25): 1657-65. PMID 24670710
 80. Olde Nordkamp LR, Brouwer TF, Barr C, et al. Inappropriate shocks in the subcutaneous ICD: Incidence, predictors and management. *Int J Cardiol*. Sep 15 2015; 195: 126-33. PMID 26026928
 81. Boersma L, Barr C, Knops R, et al. Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study. *J Am Coll Cardiol*. Aug 15 2017; 70(7): 830-841. PMID 28797351
 82. Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. *Circulation*. Aug 27 2013; 128(9): 944-53. PMID 23979626
 83. Burke MC, Gold MR, Knight BP, et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. *J Am Coll Cardiol*. Apr 28 2015; 65(16): 1605-1615. PMID 25908064
 84. Boersma L, Burke MC, Neuzil P, et al. Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction. *Heart Rhythm*. Jan 2016; 13(1): 157-64. PMID 26341604
 85. Lambiase PD, Gold MR, Hood M, et al. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. *Heart Rhythm*. May 2016; 13(5): 1066-1074. PMID 26767422
 86. Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. *N Engl J Med*. Jul 01 2010; 363(1): 36-44. PMID 20463331
 87. Theuns DA, Crozier IG, Barr CS, et al. Longevity of the Subcutaneous Implantable Defibrillator: Long-Term Follow-Up of the European Regulatory Trial Cohort. *Circ Arrhythm Electrophysiol*. Oct 2015; 8(5): 1159-63. PMID 26148819
 88. Olde Nordkamp LR, Dabiri Abkenari L, Boersma LV, et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. *J Am Coll Cardiol*. Nov 06 2012; 60(19): 1933-9. PMID 23062537
 89. Kooiman KM, Knops RE, Olde Nordkamp L, et al. Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: implications for management. *Heart Rhythm*. Mar 2014; 11(3): 426-34. PMID 24321235

90. Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. Jan 22 2013; 61(3): e6-75. PMID 23265327
91. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. Oct 02 2018; 72(14): 1677-1749. PMID 29097294
92. Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in individuals who are not included or not well represented in clinical trials. *J Am Coll Cardiol*. Sep 16 2014; 64(11): 1143-77. PMID 24820349
93. Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. *Circulation*. Jan 26 2010; 121(3): 458-77. PMID 20048212
94. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. *Heart Rhythm*. Nov 2019; 16(11): e301-e372. PMID 31078652
95. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of individuals with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. *Heart Rhythm*. Dec 2013; 10(12): 1932-63. PMID 24011539
96. Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). *Can J Cardiol*. Oct 2014; 30(10): e1-e63. PMID 25262867
97. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Implantable Automatic Defibrillators (20.4). 2018;

<https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=288>. Accessed April 20, 2020.